338 related articles for article (PubMed ID: 32877928)
1. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
[TBL] [Abstract][Full Text] [Related]
2. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma.
Koh JM; Ahn SH; Kim H; Kim BJ; Sung TY; Kim YH; Hong SJ; Song DE; Lee SH
PLoS One; 2017; 12(11):e0187398. PubMed ID: 29117221
[TBL] [Abstract][Full Text] [Related]
3. Over-diagnosis of potential malignant behavior in MEN 2A-associated pheochromocytomas using the PASS and GAPP algorithms.
Stenman A; Zedenius J; Juhlin CC
Langenbecks Arch Surg; 2018 Sep; 403(6):785-790. PubMed ID: 29779047
[TBL] [Abstract][Full Text] [Related]
4. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up.
Stenman A; Zedenius J; Juhlin CC
Surgery; 2019 Nov; 166(5):901-906. PubMed ID: 31239074
[TBL] [Abstract][Full Text] [Related]
5. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
[TBL] [Abstract][Full Text] [Related]
6. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of Nrf2 and elevated glucose uptake in pheochromocytoma and paraganglioma with SDHB gene mutation.
Kamai T; Murakami S; Arai K; Nishihara D; Uematsu T; Ishida K; Kijima T
BMC Cancer; 2022 Mar; 22(1):289. PubMed ID: 35300626
[TBL] [Abstract][Full Text] [Related]
8. The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study.
Schovanek J; Martucci V; Wesley R; Fojo T; Del Rivero J; Huynh T; Adams K; Kebebew E; Frysak Z; Stratakis CA; Pacak K
BMC Cancer; 2014 Jul; 14():523. PubMed ID: 25048685
[TBL] [Abstract][Full Text] [Related]
9. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
[TBL] [Abstract][Full Text] [Related]
10. Locally invasive recurrence or metastasis of pheochromocytoma into the liver?-clinicopathological challenges.
Tang SS; Lee JWK; Wijerethne S; Iyer SG; Hue S; En NM; Parameswaran R
World J Surg Oncol; 2022 Nov; 20(1):360. PubMed ID: 36368995
[TBL] [Abstract][Full Text] [Related]
11. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.
De Filpo G; Cantini G; Rastrelli G; Vannini G; Ercolino T; Luconi M; Mannelli M; Maggi M; Canu L
J Endocrinol Invest; 2022 Jan; 45(1):149-157. PubMed ID: 34227051
[TBL] [Abstract][Full Text] [Related]
12. The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes.
Udager AM; Magers MJ; Goerke DM; Vinco ML; Siddiqui J; Cao X; Lucas DR; Myers JL; Chinnaiyan AM; McHugh JB; Giordano TJ; Else T; Mehra R
Hum Pathol; 2018 Jan; 71():47-54. PubMed ID: 29079178
[TBL] [Abstract][Full Text] [Related]
13. Identification of Predictors of Metastatic Potential in Paragangliomas to Develop a Prognostic Score (PSPGL).
Iguchi DYV; Martins Filho SN; Soares IC; Siqueira SAC; Alves VAF; Assato AK; Yang JH; Almeida MQ; Villares Fragoso MCB; Fagundes GFC; Mendonca BB; Lourenço Junior DM; Hoff AO; Castroneves LA; Ferraz-de-Souza B; Giannella MLCC; Pereira MAA
J Endocr Soc; 2024 May; 8(7):bvae093. PubMed ID: 38799767
[TBL] [Abstract][Full Text] [Related]
14. Pheochromocytomas and paragangliomas in humans and dogs.
Galac S; Korpershoek E
Vet Comp Oncol; 2017 Dec; 15(4):1158-1170. PubMed ID: 28120550
[TBL] [Abstract][Full Text] [Related]
15. Morphological and immunohistochemical characteristics associated with metastatic and recurrent progression in pheochromocytoma/paraganglioma: A cohort study.
Wang LL; Wei XJ; Zhang QC; Li F
Ann Diagn Pathol; 2022 Oct; 60():151981. PubMed ID: 35660808
[TBL] [Abstract][Full Text] [Related]
16. SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis.
Su T; Yang Y; Jiang L; Xie J; Zhong X; Wu L; Jiang Y; Zhang C; Zhou W; Ye L; Ning G; Wang W
Front Endocrinol (Lausanne); 2023; 14():1121397. PubMed ID: 37008946
[TBL] [Abstract][Full Text] [Related]
17. Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy.
Parasiliti-Caprino M; Lucatello B; Lopez C; Burrello J; Maletta F; Mistrangelo M; Migliore E; Tassone F; La Grotta A; Pia A; Reimondo G; Giordano R; Giraudo G; Piovesan A; Ciccone G; Deandreis D; Limone P; Orlandi F; Borretta G; Volante M; Mulatero P; Papotti M; Aimaretti G; Terzolo M; Morino M; Pasini B; Veglio F; Ghigo E; Arvat E; Maccario M
Hypertens Res; 2020 Jun; 43(6):500-510. PubMed ID: 31586159
[TBL] [Abstract][Full Text] [Related]
18. Paraganglioma: not just an extra-adrenal pheochromocytoma.
Laird AM; Gauger PG; Doherty GM; Miller BS
Langenbecks Arch Surg; 2012 Feb; 397(2):247-53. PubMed ID: 22086065
[TBL] [Abstract][Full Text] [Related]
19. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances in Histopathological and Molecular Diagnosis in Pheochromocytoma and Paraganglioma: Challenges for Predicting Metastasis in Individual Patients.
Yamazaki Y; Gao X; Pecori A; Nakamura Y; Tezuka Y; Omata K; Ono Y; Morimoto R; Satoh F; Sasano H
Front Endocrinol (Lausanne); 2020; 11():587769. PubMed ID: 33193100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
